Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE versus INDERIDE 40 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE versus INDERIDE 40 25.
CHLOROTHIAZIDE vs INDERIDE-40/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Inderide-40/25 is a combination of propranolol (non-cardioselective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol reduces heart rate, myocardial contractility, and renin secretion via beta-adrenergic receptor blockade. Hydrochlorothiazide inhibits Na+/Cl- cotransporter in distal convoluted tubule, increasing excretion of Na+, Cl-, and water; also reduces peripheral vascular resistance.
500 mg to 1000 mg orally or intravenously once or twice daily.
One tablet (40 mg propranolol HCl/25 mg hydrochlorothiazide) orally twice daily; may increase to maximum of 160 mg propranolol/100 mg hydrochlorothiazide per day in divided doses.
None Documented
None Documented
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateChlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateTerminal half-life: 45–120 minutes (prolonged in renal impairment); clinical context: short duration requires frequent dosing
Propranolol: 3-6 hours (terminal); clinical context: dosing 2-3 times daily due to short half-life; may accumulate in hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal); clinical context: longer in renal impairment.
Renal: ~95% (tubular secretion); Fecal: <5%
Propranolol: extensively metabolized in liver via CYP2D6 and glucuronidation; <1% excreted unchanged in urine. Hydrochlorothiazide: ~70% excreted unchanged in urine via tubular secretion.
Category C
Category C
Thiazide Diuretic
Beta Blocker and Thiazide Diuretic
Chlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin."